IsoRay implants first cesium-131 seed

Medical isotope developer IsoRay reported that its low-dose rate (LDR) cesium-131 brachytherapy seed was implanted into a prostate cancer patient at the University of Washington Medical Center in Seattle, according to the Richland, WA-based firm.

The Cs131 seed is not yet widely available, IsoRay said. Initial production is occurring at facilities contracted with Pacific Northwest National Laboratory and the U.S. Department of Energy in Richland, WA.

Production will increase in the third quarter of 2005, when the firm opens its automated manufacturing facility in Richland. It expects to employ 250 personnel when the facility is running at full production, IsoRay said.

By staff writers
October 27, 2004

Related Reading

IsoRay inks deal with PNNL and U.S. DOE, May 11, 2004

Copyright ©

Page 1 of 461
Next Page